Histrelin
Supprelin, Supprelin La, Vantas (histrelin) is a protein pharmaceutical. Histrelin was first approved as Supprelin on 1991-12-24. It is used to treat precocious puberty in the USA. It is known to target gonadotropin-releasing hormone receptor. Vantas's patent is valid until 2026-06-16 (FDA).
| Trade Name | Supprelin, Supprelin La, Vantas |
|---|---|
| Common Name | Histrelin |
| Indication | precocious puberty |
| Drug Class | Prehormones or hormone-release stimulating peptides |
